DK3736270T3 - Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder - Google Patents

Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3736270T3
DK3736270T3 DK20183402.5T DK20183402T DK3736270T3 DK 3736270 T3 DK3736270 T3 DK 3736270T3 DK 20183402 T DK20183402 T DK 20183402T DK 3736270 T3 DK3736270 T3 DK 3736270T3
Authority
DK
Denmark
Prior art keywords
fibroset
transmebrane
cystic
modulators
power regulator
Prior art date
Application number
DK20183402.5T
Other languages
English (en)
Inventor
Robert J Altenbach
Andrew Bogdan
Sylvain Couty
Nicolas Desroy
Gregory A Gfesser
Philip R Kym
Bo Liu
Thi Thu Trang Mai
Karine Fabienne Malagu
Merayo Nuria Merayo
Olivier Laurent Picolet
Xenia B Searle
Der Plas Steven Emiel Van
Xueqing Wang
Ming C Yeung
Christopher Gaëtan Housseman
Mathieu Rafaël Pizzonero
Original Assignee
Abbvie Overseas Sarl
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Overseas Sarl, Galapagos Nv filed Critical Abbvie Overseas Sarl
Application granted granted Critical
Publication of DK3736270T3 publication Critical patent/DK3736270T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK20183402.5T 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder DK3736270T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558430P 2017-09-14 2017-09-14
US201762608846P 2017-12-21 2017-12-21
EP18779798.0A EP3681864B1 (en) 2017-09-14 2018-09-13 Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Publications (1)

Publication Number Publication Date
DK3736270T3 true DK3736270T3 (da) 2021-08-09

Family

ID=63713961

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20183405.8T DK3736267T3 (da) 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder
DK20183402.5T DK3736270T3 (da) 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder
DK18779798.0T DK3681864T3 (da) 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrose-transmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20183405.8T DK3736267T3 (da) 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18779798.0T DK3681864T3 (da) 2017-09-14 2018-09-13 Modulatorer af det cystisk fibrose-transmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder

Country Status (33)

Country Link
US (6) US10988454B2 (da)
EP (4) EP3736270B1 (da)
JP (4) JP7064072B2 (da)
KR (1) KR20200086661A (da)
CN (1) CN111954664A (da)
AU (1) AU2018332512A1 (da)
BR (1) BR112020005102A2 (da)
CA (1) CA3074945A1 (da)
CL (1) CL2020000664A1 (da)
CO (1) CO2020004249A2 (da)
CR (1) CR20200157A (da)
CY (3) CY1123761T1 (da)
DK (3) DK3736267T3 (da)
EC (1) ECSP20021913A (da)
ES (3) ES2856751T3 (da)
HR (3) HRP20210099T1 (da)
HU (3) HUE052873T2 (da)
IL (1) IL273163A (da)
LT (3) LT3736270T (da)
MA (1) MA50240B1 (da)
MD (3) MD3681864T2 (da)
MX (1) MX2020002806A (da)
PE (1) PE20210140A1 (da)
PH (1) PH12020500509A1 (da)
PL (3) PL3736270T3 (da)
PT (3) PT3736270T (da)
RS (3) RS62185B1 (da)
RU (1) RU2020113350A (da)
SG (1) SG11202002101RA (da)
SI (3) SI3736267T1 (da)
UA (1) UA125541C2 (da)
WO (1) WO2019053634A1 (da)
ZA (1) ZA202002363B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3519401B1 (en) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3897832B1 (en) * 2018-12-18 2023-10-11 Novartis AG N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a cftr mediated disease
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20220211692A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602426A (en) * 1945-10-24 1948-05-26 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
MXPA03003174A (es) * 2000-10-10 2003-07-14 Smithkline Beecham Corp Indoles substituidos, composiciones farmaceuticas que contienen dichos indoles y su uso como agentes de enlace ppar-y..
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
AU2007351454B2 (en) 2006-11-03 2013-07-18 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
KR20100049667A (ko) * 2007-08-29 2010-05-12 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 인돌 유도체
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20100134063A (ko) * 2008-03-25 2010-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제
KR20110074916A (ko) 2008-10-23 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태
DK2365972T3 (da) * 2008-11-06 2015-01-19 Vertex Pharma Modulatorer af atp-bindende kassettetransportører
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN102458122A (zh) * 2009-04-20 2012-05-16 人类健康研究所 含有哒嗪磺胺衍生物的化合物、组合物和方法
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
ES2716723T3 (es) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulación de los canales de sodio por las proteínas PLUNC
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
CN103484818A (zh) 2013-09-25 2014-01-01 京东方科技集团股份有限公司 蒸镀方法、蒸镀装置和发光器件
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
KR102132215B1 (ko) 2014-04-03 2020-07-09 삼성전자주식회사 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법
CN112250627B (zh) * 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
SG11201703391VA (en) * 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
JP2018516932A (ja) 2015-06-02 2018-06-28 アッヴィ・エス・ア・エール・エル 置換ピリジンおよび使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Also Published As

Publication number Publication date
LT3681864T (lt) 2021-02-25
RU2020113350A (ru) 2021-10-15
MA50240B1 (fr) 2021-03-31
RS61899B1 (sr) 2021-06-30
US20190077784A1 (en) 2019-03-14
SI3736267T1 (sl) 2021-09-30
PL3736270T3 (pl) 2021-11-15
EP3736270A1 (en) 2020-11-11
PT3736270T (pt) 2021-08-10
ES2856751T3 (es) 2021-09-28
MA50240A (fr) 2020-07-22
JP7064073B2 (ja) 2022-05-10
HRP20211198T1 (hr) 2021-10-29
HRP20210099T1 (hr) 2021-03-05
MD3736270T2 (ro) 2021-11-30
DK3681864T3 (da) 2021-01-25
PL3736267T3 (pl) 2021-11-15
WO2019053634A1 (en) 2019-03-21
ES2887449T3 (es) 2021-12-22
EP3736267B1 (en) 2021-05-05
PH12020500509A1 (en) 2021-05-31
SG11202002101RA (en) 2020-04-29
CA3074945A1 (en) 2019-03-21
HUE055241T2 (hu) 2021-11-29
CY1123761T1 (el) 2022-05-27
KR20200086661A (ko) 2020-07-17
EP3681864B1 (en) 2020-10-28
US10988454B2 (en) 2021-04-27
PL3681864T4 (pl) 2021-05-17
MD3681864T2 (ro) 2021-05-31
JP7064074B2 (ja) 2022-05-10
US10844041B2 (en) 2020-11-24
PL3681864T3 (pl) 2021-05-17
EP3736270B1 (en) 2021-05-05
US20200277274A1 (en) 2020-09-03
AU2018332512A1 (en) 2020-04-23
CL2020000664A1 (es) 2020-11-06
ES2881881T3 (es) 2021-11-30
US20200277276A1 (en) 2020-09-03
LT3736270T (lt) 2021-08-25
CR20200157A (es) 2021-02-16
PT3736267T (pt) 2021-08-10
ECSP20021913A (es) 2020-05-29
HRP20211200T1 (hr) 2021-10-29
BR112020005102A2 (pt) 2020-09-24
JP2022000461A (ja) 2022-01-04
EP3736267A1 (en) 2020-11-11
US20200277275A1 (en) 2020-09-03
SI3681864T1 (sl) 2021-08-31
EP3681864A1 (en) 2020-07-22
PT3681864T (pt) 2021-02-25
CY1124615T1 (el) 2022-07-22
US20210238159A1 (en) 2021-08-05
LT3736267T (lt) 2021-08-25
HUE052873T2 (hu) 2021-05-28
EP3865474A1 (en) 2021-08-18
PE20210140A1 (es) 2021-01-21
JP7064072B2 (ja) 2022-05-10
RU2020113350A3 (da) 2022-04-14
RS62190B1 (sr) 2021-08-31
HUE055050T2 (hu) 2021-10-28
MD3736267T2 (ro) 2021-11-30
RS62185B1 (sr) 2021-08-31
MX2020002806A (es) 2020-10-12
UA125541C2 (uk) 2022-04-13
CO2020004249A2 (es) 2020-08-31
CN111954664A (zh) 2020-11-17
IL273163A (en) 2020-04-30
JP2022000460A (ja) 2022-01-04
US10844042B2 (en) 2020-11-24
SI3736270T1 (sl) 2021-09-30
US10981890B2 (en) 2021-04-20
DK3736267T3 (da) 2021-08-09
US20200277273A1 (en) 2020-09-03
JP2020534360A (ja) 2020-11-26
CY1124401T1 (el) 2022-07-22
US10829473B2 (en) 2020-11-10
JP2022062093A (ja) 2022-04-19
ZA202002363B (en) 2021-06-30

Similar Documents

Publication Publication Date Title
DK3736267T3 (da) Modulatorer af det cystisk fibrosetransmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder
DK3399984T3 (da) Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf
DK3551622T3 (da) Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
DK3454871T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3459201T3 (da) Design af fælles ressourcekort over DM-RS og PT-RS
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3484865T3 (da) Somatostatinmodulatorer og anvendelser deraf
DK3364958T3 (da) Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
DK3491846T3 (da) Hørehjælpeapparat og hørehjælpeindretning
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3568914T3 (da) Strømforsyningssystem og fremgangsmåde
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3442093T3 (da) Opladningsstyreanordning og strømadapter
DK3431679T3 (da) Panelbæresystem og fremgangsmåde
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3282584T3 (da) Effektfordelingssystem og fremgangsmåde
DK3651938T3 (da) Fatning og fastgørelse af fatning
DK3304240T3 (da) Effektomformer og tilhørende strømnet
DK3639341T3 (da) Elektriske strømdelsystemer og fremgangsmåder til styring af samme
DK3841066T3 (da) Afsaltningssystem og fremgangsmåde
DE102018221635B8 (de) Kontaktierungsverfahren und System
DK3714070T3 (da) Hidtil ukendt cip2a-variant og anvendelser deraf
DK3432607T3 (da) Feedbackdæmper og høreapparat